• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Molecular targeting therapy against intracellular signaling network in gallbladder cancer

Research Project

Project/Area Number 24591008
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Gastroenterology
Research InstitutionThe University of Tokyo

Principal Investigator

SASAKI Takashi  東京大学, 医学部附属病院, 助教 (10569106)

Co-Investigator(Kenkyū-buntansha) MOURI Dai  東京大学, 医学部附属病院, 助教 (20582513)
IJICHI Hideaki  東京大学, 医学部附属病院, 講師 (70463841)
IKENOUE Tsuneo  東京大学, 医科学研究所, 准教授 (80396712)
Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords胆嚢癌 / MAPKシグナル / PI3Kシグナル / MEK阻害剤 / mTOR阻害剤 / MAPKシグナル / mTOR阻害剤
Outline of Final Research Achievements

Gallbladder cancer is the most common type with the worst prognosis among the bile duct cancers. The mechanism of disease and novel effective therapeutics still remain to be fully investigated. Analysis of human gallbladder cancer tissues demonstrated that MAPK and PI3K signaling pathways were frequently coordinately dysregulated in one third of the patients examined. We report here that the combination therapy using CI-1040, an inhibitor of MEK and RAD001, an inhibitor of mTOR, synergistically inhibited human gallbladder cancer cell proliferation in vitro and tumor growth of the xenograft model in vivo. Compared to the single treatment with CI-1040 or RAD001, the combination therapy significantly induced cell cycle arrest and apoptosis with decreased cyclin D1 expression.
These findings suggest that the double blockade of MAPK and mTOR signaling pathways might inhibit the signal crosstalk and benefit patients with advanced gallbladder cancer with hyperactivated these signalings.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report
  • Research Products

    (11 results)

All 2014 2013 2012

All Journal Article (6 results) (of which Peer Reviewed: 6 results,  Open Access: 1 results) Presentation (5 results)

  • [Journal Article] Treatment outcomes of chemotherapy between unresectable and recurrent biliary2014

    • Author(s)
      Sasaki T, et al.
    • Journal Title

      World J Gastroenterol.

      Volume: 20 Issue: 48 Pages: 18452-7

    • DOI

      10.3748/wjg.v20.i48.18452

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer.2013

    • Author(s)
      Sasaki T, et al.
    • Journal Title

      Chemotherapy

      Volume: 59 Issue: 2 Pages: 106-111

    • DOI

      10.1159/000354209

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Current status of chemotherapy for the treatment of advanced biliary tract cancer.2013

    • Author(s)
      Sasaki T, et al.
    • Journal Title

      Korean J Intern Med

      Volume: 28 Issue: 5 Pages: 515-524

    • DOI

      10.3904/kjim.2013.28.5.515

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] 肝門部胆管癌に対する内科的治療の進歩2013

    • Author(s)
      佐々木隆
    • Journal Title

      外科

      Volume: 75 Pages: 475-478

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Improvement of prognosis for unresectable biliary tract cancer.2013

    • Author(s)
      Sasaki T, et al.
    • Journal Title

      World Journal of Gastroenterology

      Volume: 19 Issue: 1 Pages: 72-77

    • DOI

      10.3748/wjg.v19.i1.72

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.2013

    • Author(s)
      Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K.
    • Journal Title

      Cancer Chemother Pharmacol.

      Volume: 71 Issue: 4 Pages: 973-979

    • DOI

      10.1007/s00280-013-2090-4

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Presentation] 胆嚢癌化学療法における内臓脂肪の臨床的意義2014

    • Author(s)
      毛利大
    • Organizer
      第22回日本消化器関連学会週間
    • Place of Presentation
      神戸
    • Year and Date
      2014-10-23 – 2014-10-26
    • Related Report
      2014 Annual Research Report
  • [Presentation] 胆道癌術後Gemcitabine不応例に対する2nd line S-1の治療成績2014

    • Author(s)
      佐々木隆
    • Organizer
      第52回日本癌治療学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-08-28 – 2014-08-30
    • Related Report
      2014 Annual Research Report
  • [Presentation] 進行胆道癌に対する集学的治療の標準化に向けて2013

    • Author(s)
      佐々木隆
    • Organizer
      日本消化器病学会大会
    • Place of Presentation
      高輪
    • Related Report
      2013 Research-status Report
  • [Presentation] 切除不能進行胆道癌に対する治療成績の検討2012

    • Author(s)
      佐々木 隆
    • Organizer
      第48回日本胆道学会学術集会
    • Place of Presentation
      東京
    • Related Report
      2012 Research-status Report
  • [Presentation] 進行胆道癌に対するGEM+CDDP併用療法の治療成績2012

    • Author(s)
      佐々木 隆
    • Organizer
      第50回日本癌治療学会学術集会
    • Place of Presentation
      横浜
    • Related Report
      2012 Research-status Report

URL: 

Published: 2013-05-31   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi